[go: up one dir, main page]

UA6537U - Scheme for prescribing carvedilol to patients with chronic cardiac insufficiency and concomitant arterial hypertension - Google Patents

Scheme for prescribing carvedilol to patients with chronic cardiac insufficiency and concomitant arterial hypertension

Info

Publication number
UA6537U
UA6537U UA20040907797U UA20040907797U UA6537U UA 6537 U UA6537 U UA 6537U UA 20040907797 U UA20040907797 U UA 20040907797U UA 20040907797 U UA20040907797 U UA 20040907797U UA 6537 U UA6537 U UA 6537U
Authority
UA
Ukraine
Prior art keywords
carvedilol
patients
cardiac insufficiency
chronic cardiac
prescribing
Prior art date
Application number
UA20040907797U
Inventor
Valentyna Kostiantyni Sierkova
Yulia Valentynivna Dombrovska
Yurii Ihorevych Monastyrskyi
Original Assignee
Vinnytsia M I Pyrohov Nat Medi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vinnytsia M I Pyrohov Nat Medi filed Critical Vinnytsia M I Pyrohov Nat Medi
Priority to UA20040907797U priority Critical patent/UA6537U/en
Publication of UA6537U publication Critical patent/UA6537U/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

The scheme for prescribing Carvedilol to the patients with the chronic cardiac insufficiency and the concomitant arterial hypertension consists in increasing the initial dose and escalating the titration dose increment. The patients with the chronic cardiac insufficiency of functional class I-II are given 25 mg of Carvedilol daily divided in two doses for 7-14 days. Then, the patients are given 37.5 mg of Carvedilol daily divided in two doses for further 7-14 days. If the drug is tolerated well, the daily dose increases up to 50 mg. The patients with the chronic cardiac insufficiency of functional class III are given initially 12.5 mg of Carvedilol daily divided in two doses for 7-14 days. If the drug is tolerated well, the daily dose increases by 12.5 mg up to 50 mg.
UA20040907797U 2004-09-24 2004-09-24 Scheme for prescribing carvedilol to patients with chronic cardiac insufficiency and concomitant arterial hypertension UA6537U (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
UA20040907797U UA6537U (en) 2004-09-24 2004-09-24 Scheme for prescribing carvedilol to patients with chronic cardiac insufficiency and concomitant arterial hypertension

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
UA20040907797U UA6537U (en) 2004-09-24 2004-09-24 Scheme for prescribing carvedilol to patients with chronic cardiac insufficiency and concomitant arterial hypertension

Publications (1)

Publication Number Publication Date
UA6537U true UA6537U (en) 2005-05-16

Family

ID=34883212

Family Applications (1)

Application Number Title Priority Date Filing Date
UA20040907797U UA6537U (en) 2004-09-24 2004-09-24 Scheme for prescribing carvedilol to patients with chronic cardiac insufficiency and concomitant arterial hypertension

Country Status (1)

Country Link
UA (1) UA6537U (en)

Similar Documents

Publication Publication Date Title
Roy et al. Lycorine: A prospective natural lead for anticancer drug discovery
MY159353A (en) Pirfenidone treatment for patients with atypical liver function
EP2216024A3 (en) Use of Ranolazine for the treatment of cardiovascular diseases
NO20075323L (en) Nutritional preparation for HIV patients
UA105191C2 (en) Treatment with pirfenidone of patients with abnormal liver function
ATE405272T1 (en) TREATMENT OF T-CELL LYMPHOMA USING 10-PROPARGYL-10-DEAZAAMINOPTERIN
UA6537U (en) Scheme for prescribing carvedilol to patients with chronic cardiac insufficiency and concomitant arterial hypertension
CR8059A (en) PHARMACEUTICAL COMPOSITION IN THE FORM OF HYDROGEL FOR TRANSDERMAL ADMINISTRATION OF ACTIVE SUBSTANCES
EA200800075A1 (en) DOSING CIRCUIT FOR WISE
DK1675611T3 (en) Therapeutic uses for C-peptide
AR049135A1 (en) COMPOSITION, METHOD, KIT AND TREATMENT WITH OXALIPLATIN AND AN EGFR INHIBITOR, AS ERLOTINIB
NO20061515L (en) Use of oxcarbazepine for the treatment of diabetic neurpathic pain and improvement of sleep
UA53291U (en) Method for treating endothelial dysfunction in aged patients with chronic heart failure
TW200515912A (en) Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep
UA33293U (en) Method for treating chronic endometritis
RU2009116087A (en) METHOD FOR MEDICINAL REDUCTION OF OXIDATIVE STRESS LEVEL IN PATIENTS WITH ARTERIAL HYPERTENSION
MD3424F1 (en) Method of treating the essential hypertension associated with marked anxious states and neuroses
UA41236U (en) Method for treating chronic systolic cardiac insufficiency
UA89009C2 (en) Method for treating community-acquired pneumonia
RU2004107473A (en) METHOD FOR THERAPY OF CHRONIC OVERSTRAINING OF AN ATHLETES
RU2007113591A (en) METHOD FOR TREATING PLATELET DYSFUNCTIONS IN PERSONS AFFECTING A METABOLIC SYNDROME
UA83947U (en) Method for treatment of congestive heart failure combined with diabetes mellitus type 2 with disynchrony
UA64176U (en) Method for correcting cerebral reactivity in patients with arterial hypertension and concomitant cerebral ischemia
UA114594U (en) METHOD OF TREATMENT OF PSORIASIS WITH CONCENTRAL ARTERIAL HYPERTENSION
UA39501U (en) Method for treating stroke